Asian Chip Stocks Mixed After Nvidia Earnings Beat 
Sweden Retail Sales Slip 0.2% in July 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Asian Currencies Steady Ahead of Warsh Speech 
Canadian Dollar Slides as Fed Rate Hike Bets Boost US Dollar 
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman 
Japan Firms Ramp Up Yen Hedging as Currency Weakness Persists 
Iran Weighs Conditions to Reopen Strait of Hormuz 
Gold Prices Slip Ahead of Fed Chair Warsh Speech 
Gold Prices Rise Toward $4,650 Ahead of Warsh’s Jackson Hole Speech 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Oil Prices Fall as Middle East Ceasefire Hopes Rise 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
Add as a preferred source on Google
Keio University researchers have successfully transplanted into a patient with a severe spinal cord injury two million neural progenitor cells derived from other people’s iPS cells as part of a clinical study, offering hope for the paralyzed.
The patient is doing well.
Over the next year, while the patient undergoes rehabilitation, the team of doctors will see how safe and effective the treatment is.
The treatment is designed for patients with “complete paralysis” who are within two to four weeks of sustaining a spinal cord injury, called the subacute phase.
The iPS cells used were stockpiled by Kyoto University’s Center for iPS Cell Research and Application.
While rehabilitation is currently the only effective treatment for a spinal cord injury, the team believes that the transplanted cells could repair damaged neural circuits and create new tissue that can transmit signals from the brain.
The team plans to do the transplant into four more patients with spinal cord injuries.
While Japan’s Ministry of Health, Labor, and Welfare approved this clinical trial in February 2019, the process of finding suitable patients was postponed due to the COVID-19 pandemic.
